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Abstract - The lack in continuity of antihypertensive treatment is one of the major common causes of uncontrolled high blood 
pressure and increased of adverse effects and medical costs associated to this disease. The current study aimed to investigate 
the relationship between a personalized strategy that guarantees the adherence to antihypertensive treatment and complications 
related to hypertension.  To do so, 586 patients hypertensive patients attending primary care institutions in La Plata Argentina, 
were randomly assigned either to an intervention group that had regular and periodically follow up contact to check treatment 
adherence or to control group. Both groups received free of charge antihypertensive medicines. The adherence was assessed 
with the adherence evaluation scale of Girerd. The presence of complications of hypertension disease (stroke, angina pectoris, 
myocardial infarct, transient ischemic attack, heart failure, kidney failure, retinopathy and death associated to this disease) 
were checked monthly.  Among the 293 patients included in the intervention group study 98.63 % (289/293) were adherents 
while only 49.14% (144/293) of the control group had continuity in the therapy. Comparing complications events developed 
by patients belonging to Intervention vs Control group after 24 month of follow up were for overall events 19.79% vs 27.98% 
(p<0.001), for stoke  0.34/1.02%(pNS); angina pectoris 4.09/6.48% (p 0.004), 0.68/1.02 (pNS), TIA 0/0.34% (p NS), heart 
failure 4.77 /7.16% (p0.003), while hospitalization associate to primary hypertension disease was 16.04/30.3% 
(p<0.001)respectively.  We can conclude that a personalized strategy to guarantee hypertension treatment adherence reduce 
the hospitalization and several complication associated to this disease.   
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I. INTRODUCTION 
   
 High blood pressure is one of the most prevalent 
chronicles diseases in the world that affects millions of 
people regardless of their race, ethnicity, or 
educational level. 
Compared to developed countries, in low-to-middle 
-income countries, the incidence of arterial 
hypertension (AHT) is increased, and awareness, 
control of the disease and adherence to treatment are at 
low levels. 
In Argentina, there is a prevalence of 39.8% of which 
has evidence that only 28% are treated and of these 
only between 7  to  43 %  achieve the goal.   When a 
AHT is not controlled, there is a high risk of multiple 
cardiovascular complications that worsen the 
prognosis and quality of life of the patient [1]. 
Among these complications are listed several events 
like stroke, myocardial infarcts, TIA, coronary 
disease, heat or renal failure, neuropathy, including 
mortality associated to this disease [2].   
Several researches demonstrated that properly blood 
pressure control reduce the incidence of stroke, acute 
coronary syndrome, myocardial infarction, congestive 
heart failure, and cardiovascular death [3]. Since AHT 
therapy results essential to avoid these complications; 
adherence to AHT treatment requires efficient 
strategies to guarantee a proper antihypertensive 
regimen to control related undesirable events [4,5]. 
Adherence to treatment is better in patients with AHT 
compared to other chronic diseases. Good compliance 
with antihypertensive therapy is a multifactorial 
process influenced by environmental factors, as well 
as the type of treatment (including dosing regimen), 
concomitant medications, clinical status, presence of 
co-morbidities, cost of treatment, and the 
doctor–patient relationship [6].  
 
In order to demonstrate if a personalized strategy to 
improve AHT therapy adherence, and if this treatment 
compliance is associate in a reduction of high blood 
pressure complications, we initiated the present study.  
 
II. MATHERIALS AND METHODS  
 
A. Type of Study 
This is a Randomized Clinical Trial where  
 
B. Universe and sample selection    
The universe of population studied was all patient 
affected by arterial hypertension that attend the first 
level of the health system of La Plata, Argentina. A 
random sample of that universe was enrolled to be 
included in this study. For patient selection, the 
following formula was used to calculate the proportion 
of finite population to be included in the study: 
                            n =.   NZ2PQ        . 
                             d2(N − 1) + Z2PQ 
 
where n is the size of the sample, N the total 
population, Z the value of z for the confidence level 
(1-alpha), p the expected proportion of complications 
associated with hypertension in the population and d 
absolute precision. A minimum of 500 people (250 per 
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group) to obtain data that were statistically significant 
(the incorporation of individuals to the two study 
groups exceeded the minimum mentioned). Including 
criteria was patients older than 18 years old, with 
uncomplicated blood hypertension and with classical 
treatment in course free of charge offered by the State 
(enalapril, losartan, amlodipine, hydrochlorothiazide, 
atenolol alone as monotherapy of in combination). 
Exclusion criteria were all patient with a history of 
complications due to arterial hypertension or with 
severe AHT that required other treatment then the one 
mentioned.   
C. Groups of Study 
After we identified potentially eligible patients from 
the medical record system and drug provision list, we 
proceed to a random stratify selection of patients in 
two groups (Control and Intervention groups). 
Randomization process was performed using a table of 
random number. Patients included in the project 
received an information package, information about 
the study, and an informed consent form. Patients 
belonging to Control group (GC) were observed in the 
usual medical care process by their primary healthcare 
(PHC) provider or their own GP. Treatments were 
carried out with free drugs obtained on request either 
in the PHC service (REMEDIAR or 
REMEDIAR-CUS Program). On the other hand, 
Intervention group (IG) was submitted to the 
intervention strategy designed for this study that is a 
personalized follow up of patients with a weekly 
contact (either physically, e-mail or by phone message 
contact) in order to remind the importance of treatment 
accomplishment and to check that adherence to the 
medication given by the same programs mentioned in 
control group.  
 
D. Period of Study:  Between 1st January 2016 to 
31st December 2018. 
E. Variables of Study:  age, gender, weight, height, 
drug treatment, treatment adherence -measure by 
MAQ survey, access to health service, number of 
medical consultation, hospital admission, inpatient 
days,  smoking status, basal cholesterol levels, 
diastolic and systolic blood pressure,  neuronal, renal 
or cardiovascular complications events that demand 
consultation or hospital admission during the study 
period. All variables were measured in both groups. 
 
F. Endpoints: Primary end point was treatment 
adherence; and Secondary end points were 
complications associated to diabetes disease. 
 
G. Statistical analysis:  We used descriptive statistics 
to summarize personal and clinical data. The impact of 
the intervention was tested in the continuity of 
treatment and in reduction of complication associate to 
AHT. We present regression coefficients, indicating 
the mean difference between the intervention and 
control group after adjusting for baseline variables. 
 
III. RESULTS  
 
Five hundred and eighty six patients were enrolled in 
the study. Two hundred and ninety were assigned to 
each group. General baseline data for both groups 
demonstrated non significant differences in the main 
variables to be study (Table 1). Baseline systolic blood 
pressure level was 143.52±22.12 and 142.94±19.24 
and diastolic blood pressure was 90.14±8,41  and 
89.87±7.95 for IG and CG respectively (table1).    
             Table 1. Patients basal data 
                                                                                                                                                                                                                                  
IG: Intervention Group; CG: Control Group; n: 
number of patients enrolled in the group of study; 
SBP: basal systolic blood pressure; DBP: diastolic 
blood pressure  
 
Patients were treated with free medication offered by 
the State government 
(REMEDIAR/REMEDIAR-CUS program). 61.43% 
of the patients received monotherapy as AHT 
medication (table2). 
 
Table 2. Patients Treatment data 
 
The percentage of treatment adherence was 98.63% 
for Intervention Group and 49.14 % for Control 
Group. Hospitalization for any cause associated to 
AHT was 16.04% and 30.03% (p < 0.001) for 
Intervention and Control group respectively. 
Complications data due to high blood pressure 
detected during 24 months of follow up period are 
available in the next table (table 3):    
 
Table 3. Complications registered during the study period 
 
G: Group; IG: Intervention Group; CG: Control 
Group; n: number of patients enrolled in the group of 
study; MI: Myocardial Infarct; TIA: Transient 
ischemic attack;. 
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Recognizing that the study groups selected for this 
work have similar characteristics and the baseline 
parameters do not have significant differences, it is 
interesting to note that even though the medication is 
totally free and available in Institutions of the First 
Level of Care of the Health System, only one 49% of 
patients have compliance in the indicated treatments. 
This point was already observed by our group in 
previous works [7].  That is to say that it is not enough 
simply to make available the free medication to 
guarantee therapeutic adherence. 
 
Many factors may influence the adherence to 
antihypertensive therapy and they are correlated with: 
gender, race, marital status, age, educational 
attainment, socioeconomic, and cultural level [8-10].   
In our work, the periodical contact with the patient was 
enough to guarantee almost a complete 
antihypertensive treatment adherence (98.63 %).  This 
method is easy a cheap, and provides excellent results 
in terms of avoiding the consequences associated with 
uncontrolled hypertensive disease. 
 
Because hypertension has no symptoms, it is common 
that people by this disease do not perceive the severity 
of the consequences of uncontrolled blood pressure 
levels. 
 
Previous studies carried out by our team, showed that 
in chronic diseases, the perception and demand for 
care is low, and that only programs that contact 
patients in their homes are more successful in avoiding 
the events associated with these diseases [11, 12].  It is 
also worth to mention that in terms of pharmacological 
management, there were more than 60% of patients 
with monotherapy and that the most of them used 
ACEI and ARA 2 as first option drugs, reaching up to 
45% between both options. Noteworthy, there was a 
low indication of thiazide diuretics as a main 
therapeutic option when it is well recognized that is 
one of the best therapeutic choice for the control of 
hypertension, especially in elderly population [13, 14].   
 
Finally, it is essential to emphasize that the adherence 
to pharmacological treatment has achieved two years 
of follow-up, halving the need for hospitalizations, 





A strategy of personalized and periodical contact to 
patients with high blood pressure by the health service 
was able to increased treatment adherence when 
compared with classical follow up based on patient’s 
spontaneous contact with the health system (98.63% 
vs 49.14 %). This strategy was also able to reduce 
Hospitalization (16.04% vs 30.03% p<0.001) and 
complications due to hypertensive disease (19.7 vs 
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